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Abstract. Exposure of cryptic actin filament fast grow- 
ing ends (barbed ends) initiates actin polymerization in 
stimulated human and mouse platelets. Gelsolin ampli- 
fies platelet actin assembly by severing F-actin and in- 
creasing the number of barbed ends. Actin filaments in 
stimulated platelets from transgenic gelsolin-null mice 
elongate their actin without severing. F-actin barbed 
end capping activity persists in human platelet extracts, 
depleted of gelsolin, and the heterodimeric capping 
protein (CP) accounts for this residual activity. 35% of 
the ~5 ~M CP is associated with the insoluble actin cy- 
toskeleton of the resting platelet. Since resting platelets 
have an F-actin barbed end concentration of N0.5 IxM, 
sufficient CP is bound to cap these ends. CP is released 
from OG-permeabilized platelets by treatment with 
phosphatidylinositol 4,5-bisphosphate or through acti- 
vation of the thrombin receptor. However, the fraction 
of CP bound to the actin cytoskeleton of thrombin- 
stimulated mouse and human platelets increases rap- 
idly to ~60% within 30 s. In resting platelets from 
transgenic mice lacking gelsolin, which have 33 % more 
F-actin than gelsolin-positive cells, there is a corre- 
sponding increase in the amount of CP associated with 
the resting cytoskeleton but no change with stimula- 
tion. These findings demonstrate an interaction be- 
tween the two major F-actin barbed end capping pro- 
teins of the platelet: gelsolin-dependent severing 
produces barbed ends that are capped by CP. Phos- 
phatidylinositol  4,5-bisphosphate release of gelsolin 
and CP from platelet cytoskeleton provides a mecha- 
nism for mediating barbed end exposure. After actin 
assembly, CP reassociates with the new actin cyto- 
skeleton. 
TIN assembly is required for the shape changes that 
occur when platelets are activated (9, 14) to per- 
form essential hemostatic tasks. The cytoplasmic 
concentration of actin in platelets is ~500  txM, 40%  of 
which  is polymerized as filaments (F-actin)  at rest (34). 
Exposure of platelets to agonists  such  as  thrombin, ini- 
tiates a signal transduction cascade that doubles the F-actin 
content (6). Actin assembly is preceded by a rapid sever- 
ing of cytoplasmic actin filaments (17). Severing amplifies 
the number of barbed ends 10-fold in permeabilized cells 
(17). As a result, platelets transform from resting discoid 
forms to activated forms having long thin filopods contain- 
ing bundles of F-actin and flat lamellae which contain an 
orthogonal array of short filaments (17). 
Barbed end actin filament capping proteins regulate the 
burst of actin polymerization in platelets. Actin filament 
barbed ends in the resting platelet are inaccessible for ac- 
tin polymerization, however, 1 min after thrombin recep- 
tor ligation up to 500 barbed ends support actin polymer- 
ization (19). Platelet shape change and actin assembly are 
blocked by addition of cytochalasins (9, 14, 17), specific in- 
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hibitors of monomer addition at the barbed end. Further- 
more, the use of cytochalasin demonstrates that the burst 
of actin assembly in response to thrombin receptor liga- 
tion  can  be  attributed  solely to  polymerization at  the 
barbed end (17). Free barbed ends result from a  signal 
transduction cascade from the thrombin receptor that in- 
cludes  activation of the small GTPase Rac which is up- 
stream of polyphosphoinositide (ppI)Ldependent "uncap- 
ping" of barbed ends (19). This places  the proteins that 
generate free barbed ends and regulate the availability of 
barbed ends for polymerization at a critical step in cyto- 
skeletal assembly and reorganization in platelets. 
We demonstrate here that platelets have capping  pro- 
tein  (CP),  the  mammalian  homologue  of  an  Acanth- 
amoeba protein (23) and nonmuscle homologue of chicken 
capZ (8), at a concentration that exceeds  the number of 
barbed ends in the resting  platelet by a factor of 10. CP 
represents the bulk of capping activity in cell extracts de- 
pleted of gelsolin by affinity chromatography. CP is found 
in both F-actin associated  and soluble compartments, and 
redistributes  upon  platelet  activation from  the  soluble 
1. Abbreviations  used in this paper: CP, capping protein; OG, n-octyl ~-D 
glucopyranoside;  ppI, polyphosphoinositide;  PRP, platelet-rich  plasma; 
TRAF, thrombin receptor activating fragment. 
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translocation of CP to the actin cytoskeleton depends on 
gelsolin. However, CP in permeabilized human platelets, 
that respond to the thrombin receptor activating fragment 
(TRAF)  by exposing  barbed  filament ends  (19), is  re- 
leased upon treatment with TRAF. Release of gelsolin 
and CP from permeabilized platelets is also achieved by 
addition of phosphatidylinositol (4,5)-bisphosphate (PI4,sP2). 
The results  suggest in platelets gelsolin and capping pro- 
tein together control actin filament barbed end exposure. 
Materials and Methods 
Reagents 
All reagents are purchased from Sigma Chemical Co. (St. Louis, MO) un- 
less otherwise noted. All antibodies were produced in the laboratory of 
John A. Cooper (Department of Cell Biology and Physiology, Washing- 
ton University Medical School, St. Louis, MO). 
Isolation of  Platelets and Platelet Fractions 
Platelets are isolated from blood by differential centrifugation and chro- 
matography as previously described (17). Briefly, blood is drawn intol/10th 
volume Aster-Jandl anticoagulant and platelet-rich plasma (PRP) is ob- 
tained by centrifugation at 110 g for 10 min. Platelets are separated from 
the serum by chromatography on a Sepharose 2B column equilibrated and 
run in 145 mM NaC1, 10 mM Hepes, 10 mM glucose, 0.2 mM Na2HPO  4, 
5 mM KC1, pH 7.4 (platelet buffer) with or without 0.3% BSA. Platelets 
are then allowed to rest for 30 min in a 37°C water bath before use. 
For large scale protein preparations, platelets are isolated from blood 
bank platelet packs that are no more than 5-d old. The platelets are sedi- 
mented by centrifugation at 800 g  for 15 min and the cell pellet resus- 
pended in 1/8th of the original volume in platelet buffer. The platelets are 
again pelleted by centrifugation at 800 g for 15 min and resuspended in the 
same volume of platelet buffer containing in addition 10 mM EGTA, pro- 
tease inhibitors (42 nM leupeptin, 10 mM benzamidine, and 0.123 mM 
aprotinin), and 1% n-octyl 13-r~-glucopyranoside  (OG). The cytoskeletal 
and soluble fraction are segregated by ultracentrifugation at 100,000 g for 
1 h, all fractions are frozen in liquid nitrogen and stored at -80°C. 
Activation of  Platelets 
Resting platelets are activated with thrombin, 1 U/ml, or the TRAF, 25 p2Vl. 
At the desired times, the platelets are permeabilized by adding 1/10 vol of 
10x PHEM (0.6 M Pipes, 0.25 M Hepes, 0.1 M EGTA, 20 mM MgCI2, pH 
6.9), 1% Triton X-100, protease inhibitors (as above), 10 p~M phallacidin 
and 20 U/ml Hirudin (thrombin-treated cells only). Cytoskeletal and solu- 
ble fractions are separated as above. Samples for SDS-PAGE are solubi- 
lized with 60 ixM Tris-HCl, 2% sodium dodecyl sulfate, 10% glycerol, 10 
}xM DTI" (SDS sample buffer) overnight at 37°C. 
In these experiments, 1 p~M phallacidin is used to prevent F-actin depo- 
lymerization after cell permeabilization, to avoid release of capping pro- 
tein due to actin filament depolymerization. The depolymerization of 
F-actin upon platelet extraction, and its prevention by addition of phalla- 
cidin, have been reported previously (17). Since phallatoxins might also 
induce actin polymerization, we used FACS  ® analysis with 1 p~M fluores- 
cein tagged phalloidin, in place of phallacidin, to confirm that the concen- 
tration of phallatoxin used in the studies presented here has no stimula- 
tory effect on F-actin content for a period of up to at least 30 min after 
platelet extraction. 
Fractionation of  Soluble Proteins  from Resting Platelets 
The supernatant obtained from OG permeabilized platelets is depleted of 
gelsolin by using affinity chromatography on an anti-gelsolin monoclonal 
IgG (C4)-CL-4B sepharose resin. The nonadherent material is collected 
and reapplied  to  ensure removal of gelsolin. Gelsolin removal is con- 
firmed by SDS-PAGE and immunoblotting. The nonadherent fraction is 
diluted with platelet buffer without NaC1 or BSA to give a final NaCI con- 
centration of 50 mM, and applied to a Pharmacia Mono Q column equili- 
brated in platelet buffer with 50 mM NaCI and no BSA. Adherent protein 
is eluted in the same buffer using a linear 50 to 500 mM NaCI gradient. 
Fractions having capping activity are pooled and concentrated by force fil- 
tration in a Centricon 10 tilter (Amicon Corp., Beverly, MA), and applied 
to a Superose 12 column equilibrated in 10 mM "Iris, 100 mM KCI, 2 mM 
MgCIz, pH 7.4 (buffer B). 
Analysis of PI4,sP2 effect on actin-associated proteins uses column puri- 
fied human platelets at 2  x  10S/ml extracted for 30 s in 0.4% OG with 
1/10 volume 10x PHEM (here the concentration of MgCI2 is 2 mM in- 
stead of 20 mM for all other experiments), 0.1 }xM phallacidin and pro- 
tease inhibitors as above and centrifuged for i  min at 10,000 g. A portion 
of the supernatant is retained for immunoblotting. From this point the 
sample is kept on ice when possible. The pellet is washed twice by resus- 
pending in lx PHEM with 0.1 }xM phallacidin and protease inhibitors and 
centrifuged again. Samples of the supernatants are recovered with each 
wash for immunoblotting. After the final wash the pellet is resuspended in 
1 x  PHEM with 0.1 ixM phallacidin and protease inhibitors in 1/4 the vol- 
ume prior to extraction. To this is added either buffer (control) or PI4,sP2 
(final concentration =  100 }xM) and incubated for 2 min and then centri- 
fuged for 1 min at 10,000 g. The supernatant is recovered and the pellet is 
resuspended in an equivalent volume. 
Viscometric and Fluorometric  Assays  for Actin 
Filament Barbed End Capping Activity 
Viscosity Assay. The effect of gelsolin-depleted platelet supernatants on 
actin's viscosity is determined in a falling ball apparatus. Samples for vis- 
cosity assays are diluted into buffer B containing 0.5 mM ATP, 0.5 mM 
2-mercaptoethanol, and 1/xM G-actin. The sample is drawn into a 100 Ixl 
capillary micropipet, allowed to stand at room temperature for 1 h, and 
then the time for a stainless steel ball bearing (outer diam 0.7 mm; The 
Microball Co., Peterborongh, NH) to fall a fixed distance through the so- 
lution is recorded. Fall times are converted to centipoises (cp) using glyc- 
erol as a standard. 
Depolymerization Assay. Pyrene-labeled F-actin, at a  concentration of 
10 IxM, is diluted to 80 nM in buffer B  (270/~1)  and the column fraction 
being tested (30-}xl each). The rate of fluorescence decrease is monitored 
in a Perkin-Elmer model LS-50 fluorimeter using 366 and 386 nm as the 
excitation and emission wavelengths, respectively. The fluorescence data 
is normalized so that time 0  =  100.  Since there are sometimes artificial 
changes in fluorescence in the first 40 s of the assay (see Fig. 4 a), the slope 
of the fluorescence decay is calculated by linear regression of the data 
points from 40-180 s. 
Electron Microscopy 
Immunogold labeling for CP is done as described previously (17). Plate- 
lets, isolated  by column chromatography, are centrifuged onto poly-L- 
lysine coated 5 mm coverslips in a 96-well microtiter plate at 1,450 g for 5 
min. Adherent cells are mechanically unroofed (18) by compressing and 
removing a second poly-L-lysine coated coverslip onto the platelet coated 
coverslip in lx  PHEM with 5  I~M phallacidin and protease inhibitors. 
This procedure exposes the underlying cytoskeleton and its attachments 
to the cytoplasmic surface of the plasma membrane. CP in these specimens 
is visualized by immunogold labeling with 8 nM particles. Alternatively, 
cytoskeletons of coverslip adherent platetets are prepared by permeabiliz- 
ing the cells in PHEM buffer containing 0.75% Triton X-100, 2 IxM phalla- 
cidin, and protease inhibitors. Rabbit anti-chicken capZ 13 subunit, affin- 
ity purified using a fusion protein containing an NHz-terminal fragment 
that is identical in both 131 and 132 subunits, at a concentration of 10 i~g/ml 
is applied in lx  PHEM, pH 7.8, containing 0.1 IxM phallacidin, and pro- 
tease inhibitors for 1 h, and then washed three times in the same buffer 
without antibody. Colloidal gold, 8 ran, coated with goat anti-rabbit IgG 
is applied to the sample in lx PHEM with 1 ixM phallacidin and protease 
inhibitors for 1 h. Unbound gold is removed by washing three times in 1 x 
PHEM with 1 ixM phallacidin and protease inhibitors. Samples are fixed 
with 1% glutaraldehyde with 0.1 }xM phallacidin, washed into distilled wa- 
ter, rapidly frozen, freeze-dried, and coated with 1.4 nm of tungsten-tan- 
talum with rotation and 2.5 nm of carbon without rotation. 
Polyacrylamide Gel Electrophoresis 
and Immunoblot Analysis 
SDS-PAGE is performed in a modified Laemmli system (28). Samples are 
run on either 12% acrylamide or linear gradient gels of 5-15%. Gels are 
stained in 0.2% Coomassie brilliant blue R250 in 20% methanol and 5% 
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tein from polyacrylamide gels using a tank transfer apparatus in 25 mM 
Tris, 195 mM glycine, and 20%  methanol onto Immobilon P membrane 
(PVDF, 0.45 Ixm; Millipore Corp., Bedford, MA). Primary and secondary 
antibodies are incubated with the membrane in PBS containing 0.05% 
Tween-20 and 5% Carnation nonfat dry milk. Chemiluminescence detec- 
tion is done using Renaissance (DuPont/NEN, Boston, MA) as described 
by the manufacturer. Densitometric and quantitative analysis of immuno- 
blots  used  a  Molecular  Dynamics  densitometer.  Two-dimensional gel 
electrophoresis is done as previously described (38). The concentration of 
CP in platelets is determined on quantitative immunoblots using a mono- 
clonal antibody specific for the chicken CP 132 subunit. This antibody is 
used since platelets have only the 132 isoform. The region of the 132 iso- 
form recognized by the antibody is highly conserved (38) and contains the 
actin binding site (22). The protein assay is standardized using a CP fusion 
protein including glutathione S transferase and the 27 carboxy-terminal 
amino acids of chicken CP 132 subunit. The immunoblot shows a linear re- 
sponse from 0.5  to  10 ng of fusion protein standard and  to increasing 
amounts of platelet lysate (Fig. 1 b). 
Antibodies used are as follows: Fig. 1 a, goat anti-chicken CP poly- 
clonal previously described (39). Fig. 1 b, mouse anti-132 subunit mono- 
clonal antibody affinity purified using the antigen a fusion protein con- 
taining the 27 COOH-terminal amino acids of chicken capping protein 132 
subunit. Fig. 1 c, rabbit anti-131 and -132 subunit polyclonal antibody and 
anti-t~ monoclonal antibody, which recognizes all known a isoforms, affin- 
ity purified. 
Results 
Human and Mouse Platelets Contain a Homologue of 
Chicken CP 
Immunoblot analysis is used to analyze platelet samples 
for heterodimeric CP. A  polyclonal antibody that recog- 
nizes both the a  (36 kD) and [3 (32 kD) subunits of chicken 
skeletal muscle CP (Fig. 1 a, lane 6) reacts strongly with a 
polypeptide with the same electrophoretic mobility as the 
chicken CP a  subunit and weakly with a band correspond- 
ing to chicken CP  13 subunit  in  lysates of whole human 
platelets (Fig. 1 a, lane 1). 
Immunoblots  of  two-dimensional  gel  electrophoresis 
demonstrate that platelets have predominantly the 132 iso- 
form of CP. Using antibodies that distinguish 132 from 131 
isoform we estimate that at least 95% of the 13 isoform is 
132 (data not shown). The 131 isoform, predominant in mus- 
cle, runs at a more acidic pI than the a  isoforms whereas 
the 132 isoform runs with a more basic pI than the a  sub- 
units  (38). An additional, minor, c~ subunit is sometimes 
seen with a more acidic pI. Whether this is an al or a2 iso- 
form remains to be determined. An additional 132 isoform, 
132', is  also  seen  in  platelets  and  has  been  reported  in 
chicken brain (38) where it is suggested that this isoform 
may arise by posttranslational modification. Cytoskeletal 
and soluble fractions from resting platelets show identical 
isoform composition (Fig. 1 c). 
The concentration of capping protein in human platelets 
is  5.6  I-LM based  on  quantitative  analysis  of one-dimen- 
sional immunoblots (Fig. 1 b). Since the actin concentra- 
tion in platelets is ,--0.5 mM (34), the ratio of capping pro- 
tein to total actin is :--1:90. 
Removal of Gelsolin from Soluble Platelet Extracts 
Reveals CP-related Actin Filament Capping Activity 
Previous  studies  demonstrated  that  gelsolin  is  a  major 
barbed end capping protein in platelets (17, 26, 27, 30, 31). 
Therefore, to determine the amount of capping activity at- 
Figure 1.  Human platelets contain actin capping protein, a homo- 
logue of chicken muscle capZ. (a) Western blot of platelet frac- 
tions using a polyclonal antibody raised against the a and 13 sub- 
units of chicken  muscle capZ.  Lane 1, whole platelets;  lane 2, 
40%  ammonium sulfate pellet of platelet soluble fraction after 
octylglucoside extraction; lane 3, 55% ammonium sulfate pellet 
of 40% ammonium sulfate supernatant;  lane 4, 70% ammonium 
sulfate  pellet of 55%  ammonium  sulfate  supernatant;  lane  5, 
pooled fractions 24-26 from Superose 12 column; lane 6, chicken 
capZ standard.  Arrows indicate  ct and [3 subunits of capZ.  (b) 
Quantitation  of capping protein in platelets.  Western  blot with 
serial dilutions of CP fusion protein (left) and serial dilutions of 
platelet total protein (right). The primary antibody used is a mono- 
clonal antibody that is specific of the 132 subunit of capping pro- 
tein. Densitometric  analysis of CP in platelets and fusion protein 
detected by western blot are linear over the concentration used. 
(c)  Two-dimensional  gel  electrophoresis  of  purified  chicken 
capZ, for reference, platelet  soluble  proteins and cytoskeletal 
fractions after permeabilization  with Triton X-100 and ultracen- 
trifugation. The primary antibodies  used recognize all a  and 13 
isoforms. 
tributable to CP,  a  partial purification and characteriza- 
tion of capping protein activity in the 1% OG lysate solu- 
ble  protein  phase  of human  platelets  first  depleted  of 
gelsolin by affinity adsorption was pursued. The polypep- 
tide composition of unbound platelet proteins after pas- 
sage through the gelsolin affinity matrix is unchanged (Fig. 2, 
compare  lanes  2  and  4)  except for the  removal  of the 
gelsolin polypeptide (band of 88 kD, Fig. 2). This proce- 
dure removes most of the gelsolin from the platelet extract 
and  reapplication  of the  unbound  fraction  to  the  anti- 
gelsolin IgG affinity column removes all gelsolin based on 
Coomassie  blue  staining  and  detection  by  immunoblot 
(Fig.  2).  We  also  validated  that  gelsolin  is  removed  in 
pyrene-actin assembly and disassembly assays.  After re- 
moval of gelsolin from the platelet supernatant, calcium- 
dependent nucleation, severing or capping  activity is  no 
longer detected (data not shown). Removal of gelsolin did, 
however, facilitate the detection of calcium-independent 
barbed end capping activities. 
Barkalow et al. Platelet F-Actin Capping Proteins  391 Figure  2.  Gelsolin  adsorption  from OG-permeabilized  platelet 
soluble fraction. Coomassie brilliant  blue stained SDS-PAGE and 
corresponding  immunoblot  (developed  with  anti-gelsolin  and 
anti-CP antibodies) of OG soluble fraction (lanes 2 and 2'). Af- 
finity adsorption using an  anti-gelsolin  column yields a  bound 
(lanes 3 and 3') and flow through fraction (lanes 4 and 4 3. The 
flow through fraction is applied to the gelsolin  affinity column a 
second  time  giving  bound  (lanes  5  and  5')  and  flow through 
(lanes  6 and 6') fractions.  Arrows indicate position of gelsolin 
and CP.  Molecular weight standards  are marked and shown in 
lane 1. From top: 195, 112, 84, 63, 35, and 32.5 kD. 
Characterization  of calcium-insensitive  capping activity 
in the gelsolin-depleted extract is accomplished by sequen- 
tial  chromatographic  separations.  The  gelsolin  depleted 
supernatant  is first applied  to an anion exchange column 
and  bound  protein  eluted  using  a  linear  NaC1  gradient. 
The unbound fraction from this column did not alter  the 
viscosity of F-actin. Viscometric analysis of adherent,  salt 
eluted fractions demonstrates calcium-independent activi- 
ties that reduce viscosity of F-actin solutions. This activity 
is broadly distributed over the column although the eluted 
fractions vary in their polypeptide composition  (data not 
shown). However, fractions eluting between  320 and 360 
mM  NaC1  consistently  decrease  the  viscosity  of F-actin. 
Fractions with this activity are complex having >20 Coo- 
massie blue stained bands ranging from 20-30 kD up to the 
prominent high molecular weight polypeptides of the plate- 
let: actin binding protein-280, spectrin, talin and myosin. 
Fractions  eluted  from  the  ion  exchange  column  with 
high activity are pooled and further fractionated by gel fil- 
tration  chromatography.  This  procedure  segregates  the 
high molecular weight proteins from smaller proteins (20- 
70-kD range)  and only the latter  (fractions 24-26), lower 
the viscosity of F-actin solutions (Fig. 3 a). Fractions with 
activity are composed of six to eight prominent polypep- 
tides,  with  a  major polypeptide  of 55  kD and two minor 
polypeptides of 30-36 kD which are the CP subunits  (de- 
tected by immunoblot Fig. 1 a, lane 5).  Based on relative 
molecular weight standards,  CP elutes from this gel filtra- 
tion column as a  globular protein in the 60-80-kD range. 
Fractions 24-26 consistently lower the viscosity of actin in 
the absence or presence of calcium ion (Fig. 3 a). 
Eluted  fractions  which  diminish  the  viscosity of actin 
gels also slow the rate of actin filament depolymerization 
when  pyrene-labeled  F-actin  is  diluted  below  its  critical 
concentration.  In the absence of added material,  dilution 
of F-actin  to  this  concentration  results  in  depolymeriza- 
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Figure 3.  Activity in the partially purified sample, obtained after 
gel filtration, is a calcium-independent actin filament barbed end 
capping protein. (a) Low shear falling ball assay of the entire in- 
cluded volume from the Superose 12 column. The assay is done 
either in 1 mM EGTA, open bars or in the presence of 0.2 mM 
CaC12, line graph. The reduction in viscosity of all actin samples 
in Ca  2÷ may be due to Ca  2÷ effects on actin polymerization. (b) 
Analysis of pyrene-labeled F-actin depolymerization in the pres- 
ence of fractions eluted from the Superose 12 column. The fluo- 
rescence measurements at time 0 are normalized to equal  100. 
Measurements are shown over the first 180 s immediately follow- 
ing dilution of F-actin into buffer containing 30 Ixl of fraction 23, 
24, 25, 26, 27, or 28. (c) Linear regression analysis from 40 to 180 s 
after start  of depolymerization assay is  used  to determine  the 
change in fluorescence over time (slope) for fractions 15-30. Un- 
der these conditions depolymerization should occur at both ends 
of the  actin  filament,  with  the  barbed  end  depolymerizing 10 
times faster than the pointed end. 
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actin. Fractions 24-26 slow the rate of F-actin depolymer- 
ization, with fractions 25 and 26 inhibiting depolymerization 
under these  conditions. The fluorescence measurements 
taken at 20-s intervals over the first 2 rain following dilu- 
tion of the F-actin in  the presence of fractions 23-28  is 
shown in Fig. 3 b.  Since there are some abnormalities in 
the fluorescence readings in the first 40 s, linear regression 
analysis to determine the slope of the fluorescence decay 
employed data from 40-180 s (Fig. 3 c). The slope of the 
fluorescence decay is directly proportional to the rate of 
actin  depolymerization. The  same  observations  are  ob- 
tained when depolymerization is  monitored in  the pres- 
ence of calcium ion (data not shown). These results sug- 
gest these fractions contain calcium-insensitive actin filament 
capping proteins. 
All fractions with calcium-insensitive barbed end cap- 
ping activity contain platelet capping protein detected in 
immunoblots with chicken CP antibody. Fig. 1 shows that 
the fractionation scheme used above enriches for human 
CP (Fig. 1 a, lane 5). An alternative method to enrich for 
CP  uses  the  gelsolin-depleted  platelet  extract  which  is 
treated  by a  series  of ammonium  sulfate precipitations, 
conditions  which  mimic  the  purification  of  capZ  from 
chicken skeletal muscle (7), (Fig. I a, lanes 2-4). Using this 
method, the CP is found in the 50 and 70%  ammonium 
sulfate pellets. This distribution is the same as reported for 
chicken skeletal muscle capZ. 
Platelet Activation Increases the Fraction of Capping 
Protein Bound to the Cytoskeleton 
The platelet actin filament-based cytoskeleton can be sep- 
arated from soluble cytoplasmic components by ultracen- 
trifugation  after  detergent  permeabilization  of the  cells 
(13). A  Coomassie-stained gel and corresponding immu- 
noblot, for one experiment, show the cytoskeletal pellets 
and soluble fractions from resting and thrombin activated 
platelets (Fig. 4 a). The relative amount of CP associated 
with the resting and activated cytoskeleton can be deter- 
mined by densitometric quantitation of immunoblots. The 
resting human platelet has 35.2  _+  4%  (from five experi- 
ments) of its total CP associated with cytoskeletal actin fil- 
aments  (Fig.  4  b).  When  platelets  are  stimulated  with 
thrombin, CP is translocated into the cytoskeleton. Fig. 4 b 
shows  that  by  20  s  after  the  addition  of thrombin  the 
amount of cytoskeletal CP increases by 1.7 times to 59.0 --- 
7.4%  (from five experiments). Maximal incorporation of 
CP into the cytoskeleton, therefore, occurs at the time of 
actin filament assembly and maximal exposure of barbed 
ends (19). Uncapping of CP-capped actin filament barbed 
ends is not detected during platelet activation, only associ- 
ation  of  CP  is  observed  suggesting  that  barbed  ends 
formed by some other mechanism  are capped by CP to 
slow actin polymerization. 
Capping Protein Is Associated with Actin Filament 
Ends in Platelets 
Anti-CP  immunogold  bound  to  the  actin  cytoskeleton 
demonstrates  the  localization  of  CP  in  glass  activated 
platelets (Fig. 5). The distribution of 8 nm anti-CP immu- 
nogold at the margin of a platelet cytoskeleton prepared 
Figure 4.  Analysis  of capping  protein in resting  and activated 
platelet  soluble and cytoskeletal fractions.  (a) Coomassie blue- 
stained  gel  (5-20%  acrylamide,  top) and immunoblot  analysis 
(15% acrylamide, using antibodies that recognize gelsolin, the a 
subunit  and the 13 subunit  of CP) bottom. 100,000 g pellets (p) 
and supernatants  (s) are shown for resting platelets (time 0) and 
platelets activated for the indicated times with 1 U/ml thrombin. 
Marks  to right  of Coomassie-stained  gel are molecular  weight 
standards from top: 195, 112, 84, 63, 52.5, 35, and 32.5 kD. (b) The 
capping protein 13 subunit, using the monoclonal antibody 3F2, is 
quantitated  using densitometric  analysis in both soluble and cy- 
toskeletal fractions and the percentage of cytoskeletal calculated 
in resting and activated platelet fractions. Error bars are standard 
deviation based on results from five experiments. 
using Triton X-100 is displayed in Fig. 5 a. Fig. 5, b and c, 
demonstrate  the  distribution  of anti-CP  immunogold  in 
unroofed platelets. Fig. 5 b shows the edge, while Fig. 5 c 
shows  the  center,  of  representative  unroofed  platelets. 
Gold particles are most abundant in the orthogonal net- 
works of short filaments at the edge of the cytoskeleton. 
The density of filaments in this region makes it difficult to 
determine if the immunogold is  on filament ends.  How- 
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unroofed cells is bound selectively at filament ends (Fig. 5,  | 
arrowheads). Gold is not associated with microtubules and  ] 
is rarely found on the cytoplasmic side of the plasma mem- 
brane in the absence of an associated actin filament. Con-  ~  as J 
trois using only secondary gold-conjugated antibody show 
no background labeling (data not shown). 
Mouse Platelets  That Lack Gelsolin Have Increased 
Amounts of Capping Protein Bound to the Cytoskeleton 
of Resting Cells 
The increase in binding of CP to the activated platelet 
cytoskeleton suggests that as the F-actin content of acti- 
vated cells increases more binding occurs. To investigate 
this further, we analyzed CP binding to the cytoskeleton in 
platelets  isolated  from transgenic  mice  lacking  gelsolin. 
Relative  to  normal  mouse  and  human  platelets,  resting 
platelets from these animals have more of their actin in- 
corporated in filaments.  Specifically, gelsolin containing 
platelets  have 40%  of their actin  polymerized into fila- 
ments compared to 53%, a 33% increase, in gelsolin null 
platelets.  The transgenic,  gelsolin null platelets,  also re- 
spond to agonist by exposing 75% fewer barbed ends (43). 
The amount of capping protein bound to cytoskeletons 
of normal resting mouse platelets, 33 ___ 7% (from 6 exper- 
iments), is similar to that found in human platelets (com- 
pare Fig. 4 and Fig. 6). Normal mouse platelets, as in human 
platelets,  also have elevated capping protein, maximally 
~50%, in the cytoskeletal fraction after thrombin stimula- 
tion (Fig. 6). Fig. 6 shows that mouse platelets from trans- 
genie animals lacking gelsolin have significantly higher 
(P  <  0.002)  resting  levels of capping  protein bound  to 
their cytoskeleton (Fig. 6). The amount of CP bound, 49 + 
3.9% (from 6 experiments), is nearly that seen maximally 
in activated human or normal mouse platelets. However, 
gelsolin null platelets fail to change their capping protein 
content in the cytoskeletal fraction when stimulated with 
thrombin (Fig. 6), despite their ability to generate barbed 
ends, albeit fewer compared to normal platelets,  and to 
polymerize actin (43). 
pH Influences the Association of Gelsolin and CP with 
the Cytoskeleton of Resting and Activated Platelets 
The pH of the extraction buffer changes the solubility of 
both gelsolin and CP, indicating that proper buffer during 
extraction is of critical importance (Fig 7). Resting plate- 
lets extracted in PHEM buffer at pH 6.0 have a surpris- 
ingly high amount of cytoskeletal-associated gelsolin, and 
a corresponding reduction in the amount of CP, associated 
with  the  cytoskeleton.  Platelets  activated  with  1  U/ml 
thrombin for 60 s and then permeabilized at pH 6.0 show a 
reduction of gelsolin and an increase in the amount of CP 
associated with the cytoskeleton, although the amount of 
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Figure 6.  CP association with 
the cytoskeleton  in platelets 
from normal mice and from 
transgenic  mice  lacking 
gelsolin. Effect of thrombin 
(1  U/ml)  activation  on cap- 
ping protein cytoskeletal  as- 
sociation  in  normal  (+/+) 
and gelsolin deficient  (-/-) 
platelets. 
CP bound is less than that found in cells permeabilized at 
neutral pH. Gelsolin is not found in the cytoskeleton of 
unstimulated cells nor in cells i  min after thrombin activa- 
tion when the cells are extracted at pH 6.9. Small amounts 
of gelsolin  (<10%)  are  found in  the  cytoskeleton tran- 
siently between 10 s and 1 min after thrombin activation 
when extracted at neutral pH (data not shown). 
1)14,51)2 Treatment Releases Gelsolin and CP But Not 
ABP-280 from OG-extracted Platelets 
Previous studies implicate PI4.sP2 in the regulation of actin 
assembly by inhibiting gelsolin's (24) and CP's (21) associ- 
ation with actin filament barbed ends. We investigated the 
effect of PI4.sP2 on the association of endogenous gelsolin, 
CP and ABP-280, an actin filament cross-linking protein, 
with the cytoskeleton of resting OG-permeabilized plate- 
lets. Treatment of platelets with 0.4%  OG permeabilizes 
them, leaving 100-200 nm holes while maintaining the sig- 
nal transduction cascade from thrombin receptor to actin 
filament barbed ends (19). Resting platelets extracted in 
0.4% OG release a portion of ABP-280, gelsolin and CP 
into  the  soluble  fraction (Fig.  8  a,  lane  1),  all  three  of 
which  are  cleared from the  soluble fraction with subse- 
quent washings (Fig. 8 a, lanes 2 and 3). After washing, the 
cytoskeletal pellet contains  11%  of the  CP,  7%  of the 
gelsolin, and 70% of the ABP in the starting material. Ad- 
dition of 100 ~M PI4,sP2 miceUes to the washed pellet ef- 
fects the  release of both gelsolin and  CP to the soluble 
fraction (Fig 8 a, lane 6) but not ABP-280 (Fig. 8 a, lane 6) 
compared to buffer treated control (Fig. 8 a, lane 5). Al- 
though  gelsolin  and  CP  are  always  released  by  PI4,sP2 
treatment the amount released is variable. This variability 
is likely a result of differences in the degree of OG perme- 
abilization  and  the  micellisation  of PI4,sP2. The percent 
gelsolin and CP released by 100 ixM PI4,sP2 from OG per- 
meabilized and washed platelets are 8.6  __+  10%  ranging 
from 1 to 25% and 8.3  ___ 6.2% ranging from 2.5 to 19%, 
respectively (based on results from seven experiments, av- 
erage  +__  SD).  Phosphatidylserine added  to washed,  OG 
extracted platelets caused no detectable enhancement of 
gelsolin  or  capping  protein  release  compared  to  buffer 
controls (data not shown). The CP released by PI4,sP2 re- 
Figure 5.  Ultrastructural  localization of capping protein in activated platelets.  (a) Triton X-100 permeabilized  platelet cytoskeleton 
showing both the dense cortical network, upper region of panel, and the underlying cytoskeleton, lower region. Gold particles are black 
dots being most abundant in the cortical cytoskeleton. (b) Unroofed platelet where the membrane at the edge of the cell has been re- 
moved. Gold particles are labeled with arrowheads.  (c) Unroofed platelet with the interior cytoskeleton exposed. Labeling is sparse 
compared to the dense cortical network where the density of actin filament ends is greatest. Since the network here is more open the 
specificity for actin filaments and ends of filaments can be seen. Gold particles are labeled with arrowheads. Bar, 200 nm. 
Barkalow et al. Platelet F-Actin Capping Proteins  395 Figure 7.  Gelsolin and CP association with the platelet cytoskele- 
ton are sensitive  to pH. Lowering the pH of extraction increases 
gelsolin  association and depresses CP association with the cyto- 
skeleton. The percentage CP and gelsolin  associated with the cy- 
toskeleton of resting or thrombin activated platelets extracted at 
pH 6.0 or 6.9 solutions are determined by densitometric analysis 
of western blots using the monoclonal antibody specific  for the 
CP 13 subunit, 3F2. 
mains soluble following ultracentrifugation (Fig. 8 b, com- 
pare  lanes  1-3  and 1 '--3') suggesting that  released  CP is 
not bound  to F-actin.  After  ultracentrifugation  most  CP 
remains in the soluble fraction compared to control where 
the bulk of CP is found in the high speed pellet. Densito- 
metric analysis of the immunoblot shown in Fig. 8 b  indi- 
cates that in the buffer control only 13% of the CP 13 sub- 
unit is recovered in the high speed supernatant,  whereas, 
in samples treated with 25 ~M PI(a,5)P  2 and 50 ~M PI(4,5)P2, 
59 and 83% are recovered, respectively. 
CP Is Released  from OG-permeabilized Platelets upon 
Thrombin Receptor Activation 
Since movement of CP to the soluble fraction could not be 
observed in intact activated platelets,  we reasoned uncap- 
ping to be masked as soluble CP concurrently capped newly 
accessible barbed ends. Addition of the TRAF to perme- 
abilized  platelets  triggers  a  release  of CP to  the  soluble 
fraction (Fig 8 b, lane 4). Of the CP released, 60% is solu- 
ble following ultracentrifugation  (Fig 8 b, lane 4'). Fig. 8 d 
shows  soluble  fractions  following  ultracentrifugation  of 
samples treated with buffer, increasing amounts of PI4,sP2, 
phosphatidylserine,  or TRAF. TRAF and PI4,sP2 cause  a 
dose dependent release of CP into the high speed superna- 
tant  but  not phosphatidylserine.  Quantitative  analysis  of 
Fig. 8 c is shown in Fig. 8 d. 
Discussion 
Greater  than  98%  of the  actin  filament  barbed  ends  in 
resting platelets are capped (17). After treatment with ag- 
onists such as thrombin (17, 19), cold (42), or phorbol 12- 
myristate  13-acetate  (PMA)  (Hartwig, J.H.,  et  al.,  manu- 
script submitted for publication) 20-25 % of the 2,000 actin 
Figure  8.  PI4.sP  2  releases 
gelsolin  and  CP  but  not 
ABP-280 while  activation of 
the  thrombin  receptor  re- 
leases  CP  from  OG- 
extracted  and washed plate- 
lets.  (a)  Immunoblot  analy- 
sis of platelet  fractions after 
extraction  with  OG  devel- 
oped  using  anti-ABP-280 
(ABP),  anti-gelsolin,  and 
anti-CP  IgG's.  Protein  re- 
maining soluble (12,000 g su- 
pernatant) following OG per- 
meabilization  is shown in lane 
1. Soluble material remaining 
following  two  successive 
buffer washes  of the OG in- 
soluble  pellet  are  shown  in 
lanes 2 and 3. Lanes 4 and 5 
are  the  pellet  and  superna- 
tant  fractions  of subsequent 
to  buffer  treated,  washed 
platelets (control),  and lane 6 is the supernatant of OG-permeabilized washed platelets treated with 100 I~M PI4.sP2. Based on sample 
volume of starting material the ratio of sample loaded in (a) are, 1 (lanes •-3):4  (lane 4):20 (lane 5 and 6). (b) Immunoblot of CP in low 
speed supernatants (12k g for 1 min, lanes 1-4), high speed supernatants (look g for 60 min, lanes l'~t'), and high speed pellets (lanes 
1" and 3") of OG-permeabilized washed platelets treated with PI(4.5)P2 or TRAF. Lanes 1, 1', and 1" are buffer treated controls. Lanes 
2 and 2' are treated with 25 ixM PI(a,5)P2; lanes 3, 3', and 3" are treated with 50 IxM PI(4,5)P2; lanes 4 and 4' are treated with 25 IxM 
TRAF. All lanes are loaded equivalently  based on volume of starting material.  (c) Immunoblot of CP in high speed supernatants (100k g 
for 60 min) from OG-permeabilized platelets.  Lanes I  and 2 are buffer treated controls; lanes 3-5 are treated with 10, 50, and 100 txM 
PI(a.5)P2, respectively; lanes 6--8 are treated with 10, 50, and 100 IxM phosphatidylserine, respectively; lanes 9-12 are treated with 2, 10, 
20, and 50 ~M TRAF, respectively.  (d) Quantitative analysis of the CP bands shown in c. Triangle indicates CP in buffer control. 
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dition and net polymerization of actin (17, 19). Barbed end 
capping proteins, therefore, both stabilize the resting cell 
by preventing filament elongation and disassembly, and in 
response  to  agonist,  allow  net  assembly  by dissociating 
from these ends. Although dissociation of barbed end cap- 
ping proteins best explains the results, the de novo forma- 
tion of actin nuclei (32) may also account for a small por- 
tion of the newly formed barbed ends in agonist activated 
platelets and other cells (reviewed in 3, 4). 
We have found that human and mouse platelets contain 
abundant amounts (5.6 I~M, a concentration equivalent to 
that of gelsolin) of heterodimeric actin filament capping 
protein. This actin filament barbed end capping protein is 
homologous  to  the  capping  protein  first  described  in 
Acanthamoeba  (23)  and  extensively studied  in  chicken 
muscle and yeast (1, 2, 8, 10). In muscle, CP is found pri- 
marily at the Z lines (8) where it is thought to cap and help 
anchor actin filaments (37). Genetically altered yeast lack- 
ing CP have aberrant actin filament organization (1). In 
Dictyostelium, capping protein participates in barbed end 
exposure when cells are treated with the chemoattractant, 
cAMP  (12,  12a,  15,  16,  20,  36).  Antibodies  specific for 
chicken CP crossreactive to bands at 32 and 36 kD, which 
comigrate with chicken CP subunits, in platelets (Fig. 1 a). 
Two-dimensional gel electrophoresis demonstrates that an 
additional t~ subunit may exist, the [3 subunit is predomi- 
nantly the [32 isoform, and the subunit composition is iden- 
tical in both cytoskeletal and soluble fractions. 
Finding CP in human and mouse platelets is not surpris- 
ing, since human and murine cDNA and gene character- 
ization have been previously reported (5, 38).  However, 
defining its role in actin polymerization is  important for 
understanding proteins that influence this essential event. 
Therefore, to assess CP's contribution to the total capping 
activity in platelets, we characterized the residual capping 
activity contained in platelet lysates after removal of en- 
dogenous gelsolin by affinity adsorption. Fractionation of 
barbed end capping activity in gelsolin-depleted platelet 
extracts by sequential ion exchange and gel filtration chro- 
matography revealed calcium-independent actin filament 
capping activity eluting only with fractions containing CP 
as determined by viscometry, F-actin depolymerization as- 
says and immunoblotting. CP is an abundant capping pro- 
tein in neutrophils  (11)  where it represents  the  bulk  of 
capping activity in cell lysates after immunoadsorption of 
gelsolin, consistent with our findings in platelets. 
Resting platelets have 0.2 mM of their actin assembled 
into F-actin. Since each filament contains ~400 monomers 
on average (17), the barbed end concentration is N0.5 IxM. 
More than sufficient CP (~35% of total CP, or 2.0 IxM) is 
associated with the resting cytoskeleton, enough to cap all 
its barbed actin filament ends. Why there is more CP asso- 
ciated with the cytoskeleton than barbed ends is not clear. 
Potential reasons for this discrepancy are: (a) our calcu- 
lations may overestimate the amount of CP. The CP con- 
centration in platelets is reported by Nachmias (33) to be 
2.2 ixM, the discrepancy with our results may be due to the 
use of different antibodies; (b) The calculation of actin fil- 
ament  number  may be  an  underestimation;  and  (c)  CP 
may associate with other components of the cytoskeleton 
in addition to barbed ends. However, even with these un- 
certainties, it is clear that >95% of actin filament barbed 
ends in resting platelets are capped and CP is the major 
barbed end capping protein associated with both the rest- 
ing and activated cytoskeleton. Immunolocalization dem- 
onstrates CP is associated with the actin cytoskeleton. Al- 
though high efficiency  immunogold labeling is not achieved, 
electron microscopy demonstrates capping protein to be 
specifically associated with cortical actin where filament 
ends are most abundant in activated platelets and, when 
ends could be identified, at only one end of filaments. 
After activation of normal human or mouse cells with 
thrombin, a portion of the previously soluble CP translo- 
cates into the cytoskeleton. However, in mouse platelets 
lacking gelsolin, activation neither increases nor decreases 
CP association with the actin cytoskeleton, although more 
capping protein is associated with the actin filament rich 
cytoskeleton  of these  resting  cells.  Either  the  filament 
ends in gelsolin-negative platelets become free by dissoci- 
ation of unknown capping proteins, de novo nucleation or 
no net change in CP-cytoskeletal interaction is observed 
because uncapping  and reassociation of CP with barbed 
ends occur rapidly. The increased proportion of CP associ- 
ated  with  the  resting  cytoskeleton  of  gelsolin-deficient 
cells is best explained by the fact that these cells have 33% 
more polymerized actin than normal gelsolin containing 
platelets (43). Although we do not know if this increase in 
F-actin results in longer filaments or more filaments, the 
increased binding of CP suggests the latter. The failure to 
bind more CP to the actin cytoskeleton when gelsolin null 
cells  activate  suggests  that  severing  by  gelsolin  creates 
most of the ends to which CP binds. How the gelsolin null 
mice are able to expose barbed ends and polymerize actin 
without detectable release of CP is not yet clear. 
The lack of CP release from cytoskeletons of thrombin- 
activated platelets was unexpected. However, this finding 
does not exclude CP dissociation as a mechanism to generate 
free barbed ends for actin monomer addition. There are 
several possibilities why we fail to measure release of CP in 
these  cells but  observe CP  uncapping  in  OG-permeabi- 
lized cells. First, platelet gelsolin is  activated within sec- 
onds of thrombin treatment. We observed, consistent with 
previously published results (31), a rapidly reversible asso- 
ciation of gelsolin with the cytoskeleton, and that only a 
fraction (5-10%) of the total gelsolin is associated with the 
activated cytoskeleton at any time. Since the gelsolin con- 
centration is ~5 IxM, and the bulk of gelsolin is inactive in 
the resting cell, the activation of gelsolin severing activity 
can increase the filament number by 10-fold from 2,000 fil- 
aments in resting platelets to as many as 20,000 following 
platelet activation by thrombin. However, biochemical as- 
says detect ~500 new barbed ends at any given time up to 
1 min after thrombin. Therefore, binding of CP to gelsolin 
generated barbed ends is likely to far exceed the number of 
ends exposed by CP-dependent uncapping. Second, disso- 
ciation and reassociation of CP to actin filament ends may 
be so rapid that we cannot detect dissociation, particularly 
since CP's affinity for barbed ends is 0.1--0.6 riM. If actin 
polymerization is driven in platelets by as little as a 10 t~M 
monomer supply, and then filaments 0.5 txm in length, as 
in the activated cell, would require only seconds to form (35). 
The  OG  permeabilization  of  platelets  leaves  behind 
plasma membrane and the thrombin signaling system re- 
Barkalow et al. Platelet F-Actin Capping Proteins  397 mains responsive to TRAF (19), a receptor activating pep- 
tide. TRAF treatment of OG-permeabilized cells exposes 
actin filament barbed ends and releases CP into the solu- 
ble fraction, showing release of CP to cause barbed end 
exposure.  We  further  exploited  the  OG-permeabilized 
platelet system to identify the capping protein(s) targeted 
by PIasP2. A portion of the gelsolin and CP remains associ- 
ated with the extracted platelets and can be released by 
PI4,sP2. The amount of gelsolin remaining in the OG-extracted 
platelets is surprisingly high compared to that seen after 
Triton X-100 suggesting that a portion of the gelsolin seen 
in the OG-permeabilized platelets  associates with mem- 
brane rather than barbed ends. This does not seem to be 
the case for CP since its recovery in OG-permeabilized, 
washed platelets is 73% less than after Triton X-100. This 
could result  from the  dissociation  of CP  from filament 
ends or loss of CP attached to the barbed ends of small ac- 
tin filament during the low speed centrifugation following 
OG permeabilization and buffer washes. Another possibil- 
ity is that ppI metabolism remains partially active after 
OG permeabilization causing release of some CP. The re- 
lease of only ~10% of the CP present in the washed plate- 
lets with Plaa.sP2 is probably due to steric hindrances influ- 
encing PIa.sP2 micelle access to CP capped barbed ends. 
Similarly, the small amount of CP released in these OG- 
permeabilized cells upon TRAF treatment is likely to re- 
sult from loss of signal transducing elements due to the ex- 
tensive washing of the OG-permeabilized cells. 
CP has been identified recently in platelets and its inter- 
action with cytoskeletal actin characterized (33). Our find- 
ings contrast strikingly with the results of Nachmias et al. 
(33)  where they observe CP  release from the  activated 
platelet cytoskeleton during the period between 5 and 15 s 
following activation with thrombin. We have failed repeat- 
edly to observe a transition of CP from the cytoskeleton to 
the soluble fraction in intact platelets activated with throm- 
bin or TRAF, despite uncovering a transition of CP to the 
soluble  fraction  in  OG-permeabilized  platelets  treated 
with either PI4,sP  2 or TRAF. Our preparations differ from 
that of Nachmias et al. in that we include phallacidin in the 
permeabilization  buffer to  prevent  depolymerization of 
small actin filaments. The amount of CP release may also 
be affected by the pH of the buffer upon platelet perme- 
abilization. Other discrepancies between our results and 
those of Nachmias et al.  (33) are in the two-dimensional 
gel analysis. We find little 131 isoform in platelets and no 
difference in segregation of CP isotypes into the soluble or 
cytoskeletal fractions. 
Our findings demonstrate that CP has an important role 
in  maintaining  the  resting  form of platelets  by binding 
available  barbed  ends.  A  stabilization  role  can  be  ex- 
tended to the activated platelet where association of CP 
to elongated actin filaments, could prevent their depoly- 
merization when the actin monomer pool size decreases. 
However, since the amount of CP in the cytoskeleton of 
activated gelsolin null platelets does not change, it is possi- 
ble that other proteins, in addition to CP, participate in 
barbed end exposure. 
ppI's are emerging as important regulators of actin fila- 
ment barbed end capping proteins. The synthesis of poly- 
phosphoinositides by the  activation of ppI kinases is an 
early event following thrombin activation of platelets (29). 
Thrombin  receptor  activation  leads  to  the  production 
ppI's phosphorylated in the D3 and D4 position. Both a 
rise in PI3,aP2 (40) and a rapid but transient rise in PI3,4,sP2 
(41) have been observed in activated platelets, although, 
the inhibition of ppI phosphorylation in the D3 position 
does not affect actin assembly in thrombin activated plate- 
lets (25). The amount of ppI's phosphorylated in the D4 
position (PIaP and PIa,sP2) increase rapidly after thrombin 
stimulation, concurrent with barbed end exposure and ac- 
tin polymerization (19). The ability of ppI's to uncap fila- 
ment  ends  in  a  permeabilized platelet  system has  been 
measured by detecting barbed end exposure and charac- 
terized to be in a signal cascade downstream from the GTPase 
Rac (19). Furthermore, a peptide, derived from the gelso- 
lin sequence, which binds PI4,sP2, inhibits thrombin recep- 
tor-dependent exposure of barbed ends  (19). Taken to- 
gether, these results and the observation of ppI dependent 
release of capping proteins from OG-permeabilized plate- 
lets presented here, suggest a model for actin polymeriza- 
tion in thrombin stimulated platelets where exposure of 
the barbed end, to allow actin polymerization, is mediated 
by ppI interaction with capping proteins. 
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